Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

NCT ID: NCT02241551

Last Updated: 2018-07-26

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 2 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-12-31
• Study Completion Date: 2017-03-03

Brief Summary

This is a prospective, randomized phase II trial. Patients diagnosed with borderline resectable pancreatic adenocarcinoma will be randomly assigned to one of two treatment arms, either mFOLFIRINOX or gemcitabine and nab-paclitaxel. After three cycles of treatment in the gemcitabine/nab-paclitaxel arm and 6 cycles in the mFOLFIRINOX arm, patients will be restaged with CT scans and if they remain borderline resectable or have improvement of their disease They will then proceed to SBRT followed by surgical resection.

Conditions

Borderline Resectable Pancreatic Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

gemcitabine/nab-paclitaxel

three cycles of treatment in the gemcitabine/nab-paclitaxel

Group Type: EXPERIMENTAL

gemcitabine/nab-paclitaxel

Intervention Type: DRUG

three cycles of treatment in the gemcitabine/nab-paclitaxel

mFOLFIRINOX

6 cycles in the mFOLFIRINOX

Group Type: EXPERIMENTAL

mFOLFIRINOX

Intervention Type: DRUG

6 cycles in the mFOLFIRINOX

Interventions

gemcitabine/nab-paclitaxel

three cycles of treatment in the gemcitabine/nab-paclitaxel

Intervention Type: DRUG

mFOLFIRINOX

6 cycles in the mFOLFIRINOX

Intervention Type: DRUG

Other Intervention Names

Gemzar; ABRAXANE; irinotecan; fluorouracil; oxaliplatin

Eligibility Criteria

Inclusion Criteria

All patients must meet the following criteria within 28 days of randomization (unless otherwise indicated) to be enrolled in the protocol:

• Histologically or cytologically proven adenocarcinoma of the pancreas. If the patient has mixed tumor with predominant adenocarcinoma pathology, they can be enrolled.
• Subjects will be staged according to the 2010 American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-4, N0 being eligible; and have a primary tumor of the pancreas (either pancreatic head, neck, uncinate process, or body/tail)
• The tumor must be deemed as being borderline resectable. Final CT confirmation of surgical staging/ eligibility will be at the discretion of the pancreatic surgeon of the patient.
• Disease is confined to locoregional site as confirmed by the CT and / or diagnostic staging laparoscopy to avoid occult peritoneal deposits. Diagnostic laproscopy will be only if absolutely required
• Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) on imaging studies CT
• Screening Endoscopic ultrasound if done prior to consent but within 6 weeks of expected randomization date it may be used.
• Karnofsky performance status greater than or equal to 70 or Eastern Cooperative Oncology Group (ECOG) performance of 0-2.
• Age > 18
• Estimated life expectance > 12 weeks
• If female patient is of child bearing potential, she must have a negative serum pregnancy test (βhCG) documented up to 72hrs prior to administration of first study drug
• Patient has screening blood work performed which includes the following (should be drawn ≤ 14 days prior to randomization)
• absolute neutrophil count (ANC) > 1.5 x 109/L
• Platelet count ≥ 100000/mm3
• Hemoglobin (HgB) ≥ 9g/dL
• aspartate aminotransferase (AST),Alanine Aminotransferase (ALT)≤ 2.5 x upper limit of normal (ULN) Total Bilirubin ≤ ULN
• Serum Cr within normal limits (WNL)
• Coagulation studies with Prothrombin Time and International Normalized Ratio (PT/INR) and partial thromboplastin time (PTT) within normal limits (±15%). • Patient has a urinalysis obtained (≤14 days prior to randomization) and the results are deemed not clinically significant by the investigator.
• Patient has no evidence of jaundice at the time of enrolment. If stent is required to alleviate jaundice, it should be metallic. If patient has a previously placed stent and this is plastic, this should be changed to metallic.
• Patient's pain symptoms have remained stable with no adjustment to analgesics within 7 days prior to randomization. Patient must be able to swallow entreat medications with no requirement for a feeding tube. Patient's must not have intractable nausea or vomiting which prohibits the patient from oral medications
• Diabetes must be controlled prior to enrollment
• Disease must be encompassed in a reasonable SBRT "portal" as defined by the treating radiation oncologist

Exclusion Criteria

• Ineligible Histology including non-adenocarcinomas, adenosquamous carcinoma, islet cell carcinomas, cystadenomas, cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile duct and ampullary carcinomas
• Evidence of distant metastasis on upright chest x-ray, CT or other staging studies
• Subjects with recurrent disease
• Prior radiation therapy to the upper abdomen or liver at the discretion of the treating radiation oncologist could impair delivery of the prescribed radiation treatment
• Prior chemotherapy
• Subjects in their reproductive age who are breast feeding or have a positive pregnancy test
• Any co-morbid condition of sufficient severity to limit full compliance with the protocol per assessment by the individual treating physician
• Concurrent active infection
• Previous or current malignancies of other histologies within the last 3 yrs prior to randomization; with the exception of cervical cancer in situ, adequately treated basal cell or squamous cell carcinoma of skin or treated low risk prostate cancer
• Patient with known historical or active infection with HIV, Hepatitis B or Hepatitis C
• Patient who has undergone recent major surgery, other than diagnostic surgical procedure within 4 weeks prior to randomization.
• Patient who has a history of allergy or hypersensitivity to any of the study drugs.
• Patients with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, interstitial pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies
• Patients with greater than 2 screening peripheral neuropathy.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Nathan Bahary, MD

OTHER

Sponsor Role: lead

Responsible Party

Nathan Bahary, MD

Associate Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

UPCI 13-143

Identifier Type: -

Identifier Source: org_study_id